Why the study?
Does SER100 exert hypotensive and bradycardic effects in rodent models of systemic and pulmonary hypertension?
Does SER100 exert hypotensive and bradycardic effects in rodent models of systemic and pulmonary hypertension?
SER100 demonstrates hypotensive and bradycardic effects in rodent models, suggesting potential as a novel therapeutic candidate for systemic and pulmonary hypertension.
Answers are grounded in this paper and cite their sources.
Does not support clinical use of SER100; leaves open translation to human hypertension trials.
SER100 exerts a chronic hypotensive and bradycardic effects in rodents, including models of systemic and pulmonary hypertension. SER100 produces its cardiovascular effects, at least in part, by inhibition of cardiac and vascular sympathetic activity. SER100 may represent a novel therapeutic candidate in systemic and pulmonary hypertension.
No takes yet. Share an insight, caveat, or question.
Villar et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: